Consolidation Immunotherapy Following Chemoradiation for Stage III NSCLC Is Standard of Care for Most Oncologists
During a Targeted Oncology Case Based Peer Perspective event, Corey J. Langer, MD, discussed options for a 63-year-old patient with stage III non–small cell lung cancer.
Kulik Addresses Transplant and Therapy in HCC
Laura M. Kulik, MD, talked through diagnosing a 77-year-old female patients with hepatocellular carcinoma as well as the treatment options for her disease during a Targeted Oncology Case Based Peer Perspectives event.
Aggarwal Examines Nivolumab Plus Ipilimumab in First-Line NSCLC
The use of chemoimmunotherapy as treatment of patients with treatment-naive stage IIIB or IV nonsquamous non–small cell lung cancer was the topic of a Targeted Oncology Case Based Peer Perspective discussion led by Charu Aggarwal, MD, MPH.
Pavlick Explores Role of Immunotherapy in Cutaneous Squamous Cell Carcinoma
During a Targeted Oncology Case Based Peer Perspective event, Anna C. Pavlick, DO, MS, MBA, discussed the case of a 69-year-old patient with cutaneous squamous cell carcinoma.
Lee Explores Treatment Options in Second- and Third-Line RCC
During a Targeted Oncology Case Based Peer Perspective event, Chung-Han Lee, MD, PhD, discussed the case of a 57-year-old woman with clear cell renal cell carcinoma.
Gergis and Rowley Examine Treatment of Moderate Chronic GVHD
During a Targeted Oncology Case Based Peer Perspective event, Usama Gergis, MD, MBA, and Scott D. Rowley, MD, reviewed the case of a 35-year-old woman with moderate chronic graft-versus-host disease.
Abou-Alfa Explores Second-Generation Tyrosine Kinase Inhibitors in HCC
During a Targeted Oncology Case Based Peer Perspectives event, Ghasson K. Abou-Alfa, MD, reviewed the case of a 77-year old woman with hepatocellular carcinoma.
FDA Approves Luspatercept for Myelodysplastic Syndrome-Associated Anemia
The FDA granted approval to luspatercept-aamt as treatment of adult patients with anemia failing an erythropoiesis stimulating agent that requires 2 or more red blood cell units over 8 weeks, that is associated with very low- to intermediate-risk myelodysplastic syndromes, intermediate-risk myelodysplastic syndromes with ring sideroblasts or myelodysplastic/myeloproliferative neoplasm.
Nivolumab Plus Sitravatinib Combo Impresses in Renal Cell Carcinoma
Combining a broad-spectrum tyrosine kinase inhibitor with an immune checkpoint inhibitor resulted in a high disease control rate in a preliminary dose-finding trial involving patients with advanced clear cell renal cell carcinoma.
MK-6482 Active in Advanced Clear Cell RCC
A fourth of patients with advanced clear cell renal cell carcinoma responded to single-agent therapy with an oral hypoxia-inducible factor–2α inhibitor, which achieved a disease control rate of 80%, a preliminary clinical trial showed.
Favorable, But Perplexing Results Observed, With Combination for mCRPC
Men with metastatic castration-resistant prostate cancer had inferior immune responses with the combination of sipuleucel-T and radium-223 but improved clinical outcomes as compared with sipuleucel-T alone, a small randomized trial showed.
Pemetrexed Injection Granted FDA Approval for Nonsquamous NSCLC and Malignant Pleural Mesothelioma
The FDA has granted approval to injectable pemetrexed for the treatment of patients with locally advanced or metastatic nonsquamous non–small cell lung cancer and for those with malignant pleural mesothelioma.
BTK Inhibitor ARQ 531 Appears Active in B-Cell Malignancies
In a preliminary clinical trial, ARQ 531, an investigational Bruton tyrosine kinase inhibitor, showed safety and clinical activity across a variety of B-cell malignancies.
Olaparib Gains FDA Approval for Indication in Pancreatic Cancer
Adult patients with deleterious or suspected deleterious germline <em>BRCA</em>-mutated metastatic pancreatic adenocarcinoma who have not had disease progression on at least 16 weeks of first-line platinum-based chemotherapy may now receive maintenance therapy with the PARP inhibitor olaparib, according to an approval from the FDA.
Risk of Recurrence Reduced With Dual Anti-HER2 Therapy in Breast Cancer
According to a pooled analysis of neoadjuvant trials presented at the San Antonio Breast Cancer Symposium, a pathologic complete response to HER2-directed neoadjuvant therapy reduced the risk of recurrence in patients with early HER2-positive breast cancer but did not eliminate it, supporting the common practice of continued anti-HER2 therapy.
High Rates of CR Observed in Follicular Lymphoma With Triplet Regimen
Patients with relapsed/refractory follicular lymphoma showed durable responses with the combination of polatuzumab-vedotin, obinutuzumab, and lenalidomide, according to results presented at the 2019 ASH Annual Meeting.
Experts Explain the Staging and Treatment of cSCC
In a Targeted Oncology live case-based peer perspectives discussion, Mark Agulnik, MD, and Simon S. Yoo, MD, discussed with a group of physicians the staging criteria and the options for treatment for patients with cutaneous squamous cell carcinoma.
Gubens Details the Management of Patients With EGFR+ NSCLC in Case Study
During a Targeted Oncology live case-based peer perspectives discussion, Matthew A. Gubens, MD, MS, reviewed with a group of physicians the localized and systemic treatment options available for the management of patients with non–small cell lung cancer.<br />
O'Shaughnessy Discusses Emerging Data That Could Affect TNBC Treatment Options
Joyce A. O’Shaughnessy, MD, led a group of physicians at a recent Targeted Oncology live case-based peer perspective event in discussion on emerging data that could affect treatment options for patients with triple-negative breast cancer in the future.
Bemcentinib Combination Induces Activity in Chemotherapy-Refractory NSCLC
Bemcentinib, a first-in-class AXL inhibitor, in combination with the PD-1 inhibitor pembrolizumab showed activity in patients with immunotherapy-naive advanced non–small cell lung cancer, according to findings from the phase II study presented at the 2019 World Conference on Lung Cancer.
Frontline Durvalumab/Chemotherapy Regimen Improves Survival in ES-SCLC
A statistically significant improvement in overall survival was demonstrated with durvalumab, a PD-L1 inhibitor, combined with chemotherapy in patients with previously untreated extensive-stage small cell lung cancer, according to findings from the phase III CASPIAN trial, presented at the 2019 World Conference on Lung Cancer.
Chari Considers Choosing Proteasome Inhibitors in Relapsed Multiple Myeloma
During a Targeted Oncology case-based peer perspectives presentation, Ajai Chari, MD, discussed with a group of physicians the treatment options available to patients with relapsed multiple myeloma. Chari explained the various treatment options and the supporting data based around a case scenario of a patient with multiple myeloma who relapses.
Raghav Works Through a CRC Patient Case After First-and Second-Line Therapy Exhaustion
At a recent Targeted Oncology live case-based peer perspectives event, Kanwal P. S. Raghav, MBBS, MD, presented a case scenario of a patient with colorectal cancer who has already gone through first- and second-line treatments. Raghav explained the treatment considerations he would make with similar patients in the clinic and the treatment options available to this patient with CRC in this setting.
Tazemetostat Receives FDA Priority Review for Metastatic or Locally Advanced Epithelioid Sarcoma
A new drug application for tazemetostat, an EZH2 inhibitor, has been granted a priority review by the FDA for the treatment of patients with metastatic or locally advanced epithelioid sarcoma not eligible for curative surgery based on data from the epithelioid sarcoma cohort of a phase II trial.
Frenette Talks Deciding Between Frontline Lenvatinib and Sorafenib in HCC
Catherine Frenette, MD, explained in a Targeted Oncology live case-based peer perspectives presentation how she treats patients with hepatocellular carcinoma across the course of disease.
Japanese First to Approve Entrectinib for NTRK+ Solid Tumors
The first regulatory approval has been granted to entrectinib in Japan. The Japanese Ministry of Health, Labour and Welfare recently approved the agent for the treatment of adult and pediatric patients with <em>NTRK </em>fusion–positive, advanced recurrent solid tumors.
Significant Survival Rates Seen With Novel Immunotherapy for Metastatic Uveal Melanoma
A novel immunotherapy agent has demonstrated significant survival rates for patients with metastatic uveal melanoma, according to updated results released at the 2018 ASCO Annual Meeting.
2 Clarke Drive Cranbury, NJ 08512